Table 1: Clinical characteristics of the total sample and across ABO blood group.

Variable Total Blood group O Blood group A Blood group B P-value
N (%) N (%) N (%) N (%)
n 215 90 (41.9%) 85 (39.5%) 40 (18.6%)
Age in years (Mean ± SD) 61.87 ± 6.14 62.14 ± 5.54 61.76 ± 6.56 62.07 ± 6.35 0.818
Gleason Score (GS) < = 6 71 (33.0%) 33 (36.7%) 21 (24.7%) 17 (42.5%)
7 112 (52.1%) 40 (44.4%) 54 (63.5%) 18 (45.0%)
> = 8 32 (14.9%) 17 (18.9%) 10 (11.8%) 5 (12.5%) 0.080
Extraprostatic Extension (EPE) No 155 (72.1%) 68 (75.6%) 56 (65.9%) 31 (77.5%)
Yes 60 (27.9%) 22 (24.4%) 29 (34.1%) 9 (22.5%) 0.253
Surgical Margin (SM) No 107 (49.8%) 45 (50.0%) 41 (48.2%) 21 (52.5%)
Yes 108 (50.2%) 45 (50.0%) 44 (51.7%) 19 (47.5%) 0.904
Seminal Vesicle Involvement (SVI) No 189 (87.9%) 80 (88.9%) 72 (84.7%) 37 (92.5%)
Yes 26 (12.1%) 10 (11.1%) 13 (15.3%) 3 (7.5%) 0.429
Pathological stage (PT) T2a, T2b 48 (22.3%) 19 (21.1%) 18 (21.2%) 11 (27.5%)
T2c 103 (47.9%) 46 (51.1%)d 37 (43.5%) 20 (50.0%)
T3 64 (29.8%) 25 (27.8%) 30 (35.3%) 9 (22.5%) 0.589
Adjuvant therapy No 160 (77.3%) 70 (78.7%) 64 (78.0%) 26 (72.2%)
Yes 47 (22.7%) 19 (21.3%) 18 (22.0%) 10 (27.8%) 0.723
Pre-op PSA (Mean ± SD) 8.89 ± 6.65 8.50 ± 5.62 9.94 ± 7.76 7.50 ± 5.90 0.128